Abivax CEO Dr. Hartmut Ehrlich talks to Scrip senior editor Lucie Ellis about the progress and next development steps for its lead clinical-stage molecule against HIV. Abivax is developing one of the first compounds, ABX464, to demonstrate an effect on human immunodeficiency (HIV) reservoirs in Phase II clinical trials. It is a first-in-class oral small anti-viral molecule, which blocks HIV replication through a unique mechanism of action. The French company is also developing ABX464 for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. A clinical study for the drug in IBD is currently enrolling patients.
for more information about BIO-EUROPE : https://ebdgroup.knect365.com/bioeurope/
+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65
Standard: +33 1 53 83 08 41
More articles in French